YNIOS PHARMA develops a safe and effective injectable treatment, TA64, administered via perfusion, and designed to protect against organ failure by supporting vascular integrity and modulating immune response.

Our development strategy is structured and progressive, initially addressing Sepsis/Septic Shock, as a first indication and optimizing label extensions by targeting other critical care diseases presenting common features where one clinical validation opens the use of TA64 to treat multiple diseases.